NEWPORT NEWS, Va., May 6 /PRNewswire/ -- Dilon Technologies announced today that it has received CE Mark (Conformite Europeenne) approval for the commercial sale of the Dilon 6800 Gamma Camera in European Union member countries. The Dilon system is a high-resolution gamma camera that enables molecular imaging of the breast and other small organs for early cancer detection.
“I am delighted that our high technology camera will now also be available to customers in Europe and other parts of the world that require the CE mark. The body of clinical evidence related to our camera’s performance and ability to detect tumors continues to mount; now medical professionals around the world will have access to this advanced diagnostic technology. Given the large international market potential for our camera, I am very excited about our company’s future growth prospects,” said Robert Moussa, Chairman and CEO.
About Dilon Technologies
Dilon Technologies is bringing innovative new medical products to the market based on research conducted at leading national research laboratories. Dilon’s cornerstone product is the Dilon 6800 Gamma Camera -- a high-resolution, anatomic-specific gamma camera, which is now being used to perform Breast-Specific Gamma Imaging (BSGI), a molecular imaging technique that images the metabolic activity of breast lesions through radiotracer uptake. Several leading medical centers around the country are now offering BSGI to their patients, including: Beth Israel Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Alexian Brothers Medical Center, Chicago; Methodist Hospital, Philadelphia; and West Valley Imaging, Las Vegas.
To find out more about BSGI or the Dilon 6800 Gamma Camera please visit http://www.dilon.com
CONTACT: Nancy F. Morter of Dilon Technologies, cell, +1-757-589-3914,
office, +1-757-269-4910, x02, nfmorter@dilon.com
Web site: http://www.dilon.com/
